000 | nab a22 7a 4500 | ||
---|---|---|---|
999 |
_c15962 _d15962 |
||
003 | PC15962 | ||
005 | 20210304100922.0 | ||
008 | 200602b xxu||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_983 _aMorales Ruiz, Enrique _eNefrología |
||
100 |
_9417 _aGutiérrez Martínez, Eduardo _eNefrología |
||
245 | 0 | 0 |
_aCinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. _h[artículo] |
260 |
_bNephrology (Carlton, Vic.), _c2014 |
||
300 | _a19(2):84-93. | ||
500 | _aFormato Vancouver: Torregrosa JV, Morales E, Díaz JM, Crespo J, Bravo J, Gómez G et al; CINAREN Study Group. Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology (Carlton). 2014 Feb;19(2):84-93. | ||
501 | _aPMID: 24428216 | ||
504 | _aContiene 47 referencias | ||
520 | _aAims: Our aim was to evaluate the long-term effect of cinacalcet in patients with hypercalcaemic secondary hyperparathyroidism (SHPT) after renal transplantation (RT) in order to expand real-world data in this population. Methods: We performed a multicentre, observational, retrospective study in 17 renal transplant units from Spain. We collected data from renal recipients with hypercalcaemic (calcium >10.2 mg/dL) SHPT (intact parathyroid hormone (iPTH) > 120 pg/mL) who initiated cinacalcet in the clinical practice. Results: We included 193 patients with a mean (standard deviation (SD)) age of 52 (12) years, 58% men. Cinacalcet treatment was initiated at a median of 20 months after RT (median dose 30 mg/day). Mean calcium levels decreased from a mean (SD) of 11.1 (0.6) at baseline to 10.1 (0.8) at 6 months (9.0% reduction, P < 0.0001). Median iPTH was reduced by 23.0% at 6 months (P = 0.0005) and mean phosphorus levels increased by 11.1% (P < 0.0001). The effects were maintained up to 3-years. No changes were observed in renal function or anticalcineurin drug levels. Only 4.1% of patients discontinued cinacalcet due to intolerance and 1.0% due to lack of efficacy. Conclusions: In renal transplant patients with hypercalcaemic SHPT, cinacalcet controlled serum calcium, iPTH and phosphorus levels up to 3 years. Tolerability was good. | ||
710 |
_986 _aServicio de Nefrología |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc15962.pdf _ySolicitar documento |
||
942 |
_2ddc _cART _n0 |